BR9914568A - Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii - Google Patents

Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii

Info

Publication number
BR9914568A
BR9914568A BR9914568-5A BR9914568A BR9914568A BR 9914568 A BR9914568 A BR 9914568A BR 9914568 A BR9914568 A BR 9914568A BR 9914568 A BR9914568 A BR 9914568A
Authority
BR
Brazil
Prior art keywords
insulin
type
formulation
diabetes
aqueous formulation
Prior art date
Application number
BR9914568-5A
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9914568A publication Critical patent/BR9914568A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FORMULAçãO AQUOSA DE INSULINA, PREPARAçãO DE INSULINA E MéTODO DE TRATAMENTO DE DIABETES DO TIPO I OU DO TIPO II". é apresentada uma formulação de insulina estável, aquosa, adequada para aporte pulmonar. A formulação é composta de insulina ou um análogo da mesma, 2 a 5 íons de Zn^ 2+^ por 6 moléculas de insulina, 3 a 18 moléculas fenólicas por 6 moléculas de insulina, e mentol. O cheiro característico de mentol mascara a presença de fenóis na formulação sem afetar a estabilidade química e física da formulação.
BR9914568-5A 1998-10-16 1999-10-15 Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii BR9914568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801326 1998-10-16
PCT/DK1999/000557 WO2000023099A1 (en) 1998-10-16 1999-10-15 Insulin preparations for pulmonary delivery containing menthol

Publications (1)

Publication Number Publication Date
BR9914568A true BR9914568A (pt) 2001-07-03

Family

ID=8103609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914568-5A BR9914568A (pt) 1998-10-16 1999-10-15 Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii

Country Status (20)

Country Link
EP (1) EP1121145B1 (pt)
JP (1) JP2002527488A (pt)
KR (1) KR20010080132A (pt)
CN (1) CN1323220A (pt)
AT (1) ATE216258T1 (pt)
AU (1) AU758108B2 (pt)
BR (1) BR9914568A (pt)
CA (1) CA2346884A1 (pt)
CZ (1) CZ20011133A3 (pt)
DE (1) DE69901314T2 (pt)
DK (1) DK1121145T3 (pt)
ES (1) ES2177324T3 (pt)
HU (1) HUP0103606A3 (pt)
IL (1) IL142002A0 (pt)
NO (1) NO20011841L (pt)
PL (1) PL347171A1 (pt)
PT (1) PT1121145E (pt)
UA (1) UA67798C2 (pt)
WO (1) WO2000023099A1 (pt)
ZA (1) ZA200102068B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354376T1 (de) 1999-10-14 2007-03-15 Pola Chem Ind Inc Zusammensetzungen für die elektroporation
EP1222931B1 (en) * 1999-10-15 2006-06-07 Pola Chemical Industries Inc. Percutaneous absorption promoters for electroporation
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
ATE369146T1 (de) * 1996-06-20 2007-08-15 Novo Nordisk As Insulinpreparation mit mannitol
ATE219942T1 (de) * 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält

Also Published As

Publication number Publication date
HUP0103606A2 (hu) 2002-02-28
CZ20011133A3 (cs) 2001-08-15
KR20010080132A (ko) 2001-08-22
NO20011841L (no) 2001-06-15
AU758108B2 (en) 2003-03-13
PT1121145E (pt) 2002-09-30
EP1121145A1 (en) 2001-08-08
JP2002527488A (ja) 2002-08-27
CA2346884A1 (en) 2000-04-27
DE69901314D1 (de) 2002-05-23
HUP0103606A3 (en) 2002-05-28
PL347171A1 (en) 2002-03-25
WO2000023099A1 (en) 2000-04-27
ATE216258T1 (de) 2002-05-15
DK1121145T3 (da) 2002-08-12
IL142002A0 (en) 2002-03-10
NO20011841D0 (no) 2001-04-10
UA67798C2 (uk) 2004-07-15
CN1323220A (zh) 2001-11-21
ES2177324T3 (es) 2002-12-01
DE69901314T2 (de) 2002-11-21
EP1121145B1 (en) 2002-04-17
ZA200102068B (en) 2001-10-12
AU6189099A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
BR9914585A (pt) Formulação aquosa de insulina, preparação de insulina, e, método de tratamento de diabetes do tipo i ou do tipo ii
PT1121145E (pt) Preparacoes de insulina contendo mentol e destinadas a administracao via pulmonar
CO4410203A1 (es) Formulaciones de analogos de insulina
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR9914507A (pt) Concentrado de substância ativa com formoterol, adequado para armazenagem
CY1110136T1 (el) Συνθεσεις ξηρης σκονης με βελτιωμενη διασπαρσιμοτητα
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
BR0315868A (pt) Método para tratar ou melhorar infecção pulmonar em um paciente portador de fibrose cìstica; e método para tratar ou melhorar infecção pulmonar em um animal
D’Agostini et al. Chemoprevention of smoke-induced alopecia in mice by oral administration of L-cystine and vitamin B6
Morris Uptake of acetaldehyde vapor and aldehyde dehydrogenase levels in the upper respiratory tracts of the mouse, rat, hamster, and guinea pig
BR9806895A (pt) Nova formulação; apresentando densidade volumétrica, quanto derramada, de 0,20 a 038 g/ml, compreendendo formoterol
BR0007632A (pt) Composições sinérgicas antimicrobianas para lavagem da pele
BR9805586A (pt) Composições em pó.
DE69916695D1 (de) Verwendung mindestens eines Hydroxystilbene als Mittel zur Verringerung der Adhäsion von Mikroorganismen
He et al. Application of Direct Analysis in Real Time–High Resolution Mass Spectrometry to Investigations of Induced Plant Chemical Defense Mechanisms—Revelation of Negative Feedback Inhibition of an Alliinase
BR9713974A (pt) Composição farmacêutica, processo para preparação e uso da mesma, e, processo de tratar um distúrbio de agregação de plaquetas
BR9912578A (pt) Composição para refrescar as narinas e as cavidades dos seios nasais.
Przuntek et al. The protective effect of 1-tert. butyl-4, 4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
BR9914945A (pt) Processo para proporcionar terapiacosmética/medicinal
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática
BR0012618A (pt) Aplicação de pelo menos um extrato de uma planta do gênero lannea em uma composição cosmética ou dermofarmacêutica
EA200702207A1 (ru) Смягчающее раздражение средство от кашля, содержащее экстракты из исландского мха и просвирника
Silva et al. Cone-beam computed tomographic evaluation of dimensional hard tissue changes following alveolar ridge preservation with leucocyte and platelet-rich fibrin techniques: a pilot study
CHANG et al. Chronic wound: Pathogenesis and current treatments
KR20220033665A (ko) 흡입하여 상기도와 폐의 바이러스 및 세균을 사멸하는 약학적 조성물

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.